Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.

Cancer investigation - 21 Oct 2017

Hocker James R, Deb Subrato J, Li Min, Lerner Megan R, Lightfoot Stan A, Quillet Aurelien A, Hanas R Jane, Reinersman Matthew, Thompson Jess L, Vu Nicole T, Kupiec Thomas C, Brackett Daniel J, Peyton Marvin D, Dubinett Stephen M, Burkhart Harold M, Postier Russell G, Hanas Jay S

Abstract excerpt

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Adhesion

Share to Databases, Protein

Share to Diagnosis, Differential

Share to Lymphocytes

Share to Proteomics

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 28949774
DOI: 10.1080/07357907.2017.1373120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.PMID 28949774Read ↗

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapySemantic proximity Read ↗

Identification of a Biomarker Panel for Early Detection of Lung Cancer PatientsSemantic proximity Read ↗

Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic TargetsSemantic proximity Read ↗

A novel open access multimodal dataset of nodule imaging and circulating proteome from a lung cancer screening cohortSemantic proximity Read ↗

A Single-Aliquot, Enrichment-Free Workflow for High-Throughput Plasma Proteome and N-Glycoproteome ProfilingSemantic proximity Read ↗

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implicationsSemantic proximity Read ↗

Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancerSemantic proximity Read ↗

Molecular & Translational Biology of the Blood-Based VeriStrat® Proteomic Test Used in Cancer Immunotherapy Treatment GuidanceSemantic proximity Read ↗

Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray ValidationSemantic proximity Read ↗

Poor prognosis of stage I lung adenocarcinoma patients determined by elevated expression over pre/minimally invasive status of COL11A1 and THBS2 in the focal adhesion pathwaySemantic proximity Read ↗

Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

New approaches for biomarker discovery in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.